SETD2 and renal carcinoma: In addition, Chinese ccRCC-TT patients had a higher mutation frequency of SETD2 (19% vs. 7%, Fisher’s exact test, p = 0.04278, Fig. 3b), a H3K36 methyltransferase whose inactivation promoted renal cancer branched evolution22 and whose overexpression in gastric cancer cell lines significantly inhibited cell proliferation, migration, and invasion23.